Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Acorda Therapeutics (ACOR) is now available.
Acorda Therapeutics, Inc. has initiated voluntary Chapter 11 proceedings and is working to sell its assets for $185 million to Merz Pharmaceuticals, LLC, subject to higher bids and court approval. Concurrently, the company has secured debtor-in-possession financing to maintain operations, with terms including a $60 million credit facility. These strategic moves aim to stabilize the company’s operations while they navigate through bankruptcy and restructuring efforts.
See more insights into ACOR stock on TipRanks’ Stock Analysis page.